longstand
discord
enigma
persist
specif
properti
antibodi
ab
effect
prevent
limit
mani
viral
infect
mammal
turn
failur
deciph
key
complex
ad
headwind
abbas
therapeut
approach
ration
vaccin
design
recent
experiment
approach
emergedand
continu
emergefor
discern
function
role
ab
structur
especi
fc
portion
antibodi
combat
viral
infect
vivo
wide
rang
vitro
measur
antibodi
activ
neutral
antibodydepend
cell
mediat
cytotox
adcc
term
repres
oper
notion
defin
particular
given
assayar
pois
assign
relev
reliabl
forecast
outcom
infect
sever
emerg
technic
opportun
clariti
attent
drawn
three
realm
increas
array
known
modif
engin
ab
affect
vivo
activ
improv
murin
model
involv
knockout
knockin
host
gene
includ
fc
receptor
develop
addit
virolog
design
tool
differenti
ab
act
primarili
inhibit
viral
entri
antibodi
mainli
target
viral
antigen
ag
cell
surfac
illustr
opportun
either
zoonot
emerg
spillov
ancient
humanadapt
virus
draw
exampl
wide
rang
virus
affect
human
network
interact
viru
host
complic
repres
complex
adapt
system
abmedi
immun
one
import
part
despit
bewild
complex
use
gener
emerg
vivo
verita
colloqui
tautolog
use
refer
viral
vaccin
therapi
correl
protect
protect
direct
test
effect
human
trial
ideal
benchmark
licensur
vaccin
therapi
human
use
howev
case
human
test
unfeas
uneth
indirect
rational
product
licensur
must
establish
basi
anim
model
human
health
predomin
ultim
concern
research
develop
standard
benchmark
relev
meaning
vitro
assay
along
nonhuman
model
diseas
sometim
necessari
surrog
human
efficaci
trial
vitro
assay
highli
use
possibl
statist
correl
protect
also
poor
reflect
complex
realiti
wit
abund
exampl
neutral
bind
titer
hemagglutinationinhibit
assay
inadequ
best
mislead
worst
full
wish
know
antivir
ab
found
ab
limit
sometim
exacerb
virusprecipit
diseas
bodi
anim
scientif
narr
immun
microbi
pathogen
proceed
wave
peak
trough
emphasi
phagocyt
cell
ab
cell
innat
immun
regulatori
signal
genom
analys
immun
repertoir
mechan
pathogen
evas
host
respons
forth
confound
shift
perceiv
import
variou
aspect
immun
differ
understand
oper
term
acronym
use
manuscript
intend
mean
shown
box
context
recognit
alreadi
exist
excel
recent
review
discret
aspect
fcrdepend
antivir
immun
aspir
offer
brief
possibl
holist
view
one
import
aspect
virushost
interact
interact
ab
viral
ag
fcr
fcrbear
cell
share
anticip
excit
emerg
technolog
may
offer
new
experiment
insight
complex
process
previous
suspect
unapproach
virus
yield
long
ago
empir
approach
vaccin
ab
therapi
led
progress
eg
jenner
pasteur
theiler
salk
sabin
hilleman
due
tremend
credit
insight
invent
bold
dog
determin
mani
virus
surrend
easili
either
serendip
brillianc
advanc
exampl
promis
vaccin
ab
therapi
yet
complet
costli
uncertain
journey
licensur
intract
previous
orphan
problem
research
direct
restrict
attent
abmedi
immun
viral
infect
three
major
interrel
question
aris
path
vaccin
therapi
figur
ab
specif
respons
protect
desir
breadth
safeti
characterist
ab
import
protect
especi
fc
part
molecul
answer
known
might
vaccin
configur
elicit
desir
specif
type
ab
latter
question
immunogen
immunodomin
proven
problemat
divers
human
popul
ration
shape
immun
respons
eg
fine
specif
type
durabl
remain
perhap
greatest
challeng
immunolog
focu
experiment
approach
precursor
question
kind
ab
respons
desir
specif
hypothes
drawn
provision
vitro
correl
protect
might
withstand
test
vivo
verac
previou
review
probe
depth
matter
vitro
viru
neutral
doesand
sometim
notalign
ab
capac
prevent
mitig
viral
diseas
vivo
emphas
redund
protect
mechan
typifi
celltarget
antibodi
ctab
ie
ab
neutral
mark
virusinfect
cell
interact
variou
popul
fc
receptor
fcr
bear
cell
well
complement
mani
complex
previous
note
along
kind
protect
function
may
may
requir
fcr
interact
summar
box
simplifi
narr
manuscript
term
fcr
use
shorthand
fc
gamma
receptor
unless
otherwis
specifi
steep
larg
array
known
fcr
immun
effector
cell
well
nonclass
fcbind
receptor
homolog
wider
array
cell
acknowledg
choic
breviti
even
greater
narr
complex
point
toward
mani
review
avail
eg
refer
citat
tabl
therein
like
fashion
sake
breviti
simplic
emphasi
fc
igg
molecul
despit
mani
import
uncertainti
antivir
interf
synerg
role
igm
iga
even
ige
host
immun
virus
remind
reader
steep
virolog
fundament
featur
viruscel
interact
context
adapt
immun
respons
illustr
figur
draw
attent
import
viral
replic
cycl
timeandloc
distinct
abdepend
neutral
abdepend
celltarget
may
occur
cycl
rational
part
immun
system
mitig
rather
prevent
infect
special
case
earli
entryassoci
target
adcc
best
describ
hiv
cover
previou
review
parenthet
affirm
complementari
interact
natur
ab
cell
immun
larger
topic
consid
moreov
figur
depict
event
singlecel
level
reserv
elsewher
discuss
larger
complex
local
distant
viral
spread
infect
host
viral
persist
latenc
biolog
system
drive
ultim
outcom
host
surviv
viral
spread
new
host
realm
ctab
expect
antivir
ab
least
partial
inform
literatur
abmedi
suppress
elimin
tumor
cell
growth
vivo
fact
human
data
ab
therapi
design
elimin
cellsor
otherwis
interact
cell
surfac
achiev
biolog
effectar
advanc
oncolog
autoimmun
virolog
result
mani
licens
ab
therapi
human
use
case
tumor
cell
elimin
function
adcc
complementmedi
cytolysi
cmc
monocytemacrophagemedi
killingal
categori
activ
welldissect
yet
poorli
understoodar
appreci
major
immun
mechan
box
brief
guid
fraught
languag
neutral
viru
neutral
oper
term
typic
refer
observ
abdepend
decreas
viral
infect
gene
product
antigen
tag
genom
spread
phenomenon
particular
vitro
assay
adcc
abdepend
cell
mediat
cytotox
collect
oper
assaydefin
term
root
mani
possibl
vari
nonredund
vitro
assay
measur
ferdepend
activ
facilit
ferbear
cell
readout
target
cell
lysi
phagocytosi
trogocytosi
nk
cell
activ
granzym
releas
ex
vivo
fer
bind
cmc
abdepend
complementmedi
cytotox
typic
refer
direct
indirect
measur
lysi
antigenbear
cell
presenc
specif
ab
along
heatlabil
protein
known
presum
execut
full
complement
cascad
relat
assay
requir
addit
ferbear
cell
includ
cdcc
complementdepend
cellmedi
cytotox
cdcp
complementdepend
cellmedi
phagocytosi
protect
sometimesambigu
term
refer
sever
favor
outcom
prevent
viral
infect
steril
immun
postinfect
control
viral
load
mitig
acut
diseas
without
viral
clearanc
case
latent
persist
infect
sustain
remiss
symptom
along
reduc
viral
load
diminish
transmiss
common
languag
agreement
upon
mean
term
often
miss
discuss
abmedi
immun
virus
import
term
shown
use
manuscript
background
discuss
neutral
adcc
provid
previous
cdcp
elsewher
consid
manipul
routin
develop
seek
optim
fc
order
maxim
therapeut
effect
proinflammatori
respons
undesir
minim
unhelp
inflamm
clinic
trial
similar
clinic
endeavor
human
virolog
unfeas
uneth
nevertheless
judg
relev
tumor
model
reflect
consider
ab
act
virusinfect
cell
fcdepend
fashion
box
structurefunct
consider
antivir
antibodi
may
confer
protect
fcindepend
abbind
suffici
fe
serv
halflif
valenc
fcdepend
abbind
necessari
insuffici
fe
requir
one
function
neutral
ie
ab
act
sole
antagonist
viral
bind
entri
launch
mani
common
assay
aggreg
virion
function
suppress
number
infecti
unit
antagon
viral
assembl
eg
competit
inhibitor
trimmer
format
requir
cleavag
antagon
viral
releas
process
eg
antineuraminidas
antagon
viral
virul
factor
otherwis
exacerb
diseas
promot
intercellular
spread
aid
transmiss
opson
ab
exploit
fer
redirect
infecti
virion
insuscept
cell
eg
neutrophil
celltarget
antibodi
ctab
requir
fe
receptor
fer
interact
manifest
antivir
effect
adcc
measur
exampl
direct
lysi
infect
cell
trogocytosi
rfadcc
phagocytosi
granzym
releasesign
nk
complement
activ
lytic
cascad
pleotrop
effect
partial
complement
activ
mani
potenti
interact
see
box
mean
term
protect
manuscript
discuss
addit
refer
phenomena
refer
past
review
figur
adapt
immun
cellular
level
window
opportun
viru
enter
cell
multipl
infect
around
infecti
unit
iu
per
cell
thu
noninfecti
particl
even
higher
ratio
disassembl
make
new
protein
genom
way
make
virion
target
avail
immun
system
chang
convent
neutral
ab
inactiv
sequest
viru
extracellularli
either
infect
viru
emerg
fcrbear
cell
facilit
extracellular
clearanc
fcrbear
cell
virusresist
addit
proteinssuch
complement
cascadecan
augment
opson
viral
replic
either
cell
recogn
mhcassoci
peptid
celltarget
ab
ctab
recogn
emerg
preassembl
protein
disrupt
cell
integr
therebi
diminish
viral
yield
per
cell
burst
size
manyfold
spare
uninfect
cell
accru
exponenti
case
welldescrib
hiv
enter
virion
display
new
earli
ctab
target
viral
spike
rearrang
coincid
receptor
engag
emphasi
manuscript
upon
recent
emerg
experiment
tool
deciph
vivo
effect
fcfcr
interact
result
protect
includ
involv
ab
shown
score
posit
vitro
neutral
assay
adcc
assay
overwhelmingli
immunolog
data
nonhuman
speci
come
mous
model
inbr
mous
strain
myriad
research
reagent
allow
complex
cell
ab
transfer
virolog
howev
mice
tend
wholli
partial
resist
infect
diseas
caus
human
pathogen
greatest
interest
compromis
sometim
found
serial
passag
viru
mice
achiev
semblanc
human
diseas
protect
mani
year
even
palat
model
viral
diseas
mice
earli
data
suggest
import
role
fc
abmedi
resist
certain
virus
data
gener
unconvinc
assign
clear
relev
fc
technic
limit
wit
necessari
panel
virusspecif
monoclon
antibodi
mab
ident
paratop
ag
combin
site
differ
fc
moieti
unachiev
consequ
preponder
evid
murin
mab
subtyp
gener
protect
especi
ctab
less
definit
fab
f
ab
fragment
ab
almost
exclus
nonprotect
poorli
directli
compar
intact
ab
fragment
neutral
vitro
short
halfliv
vivo
attempt
deplet
fcrbear
cell
vivo
confound
overal
toxic
secondari
effect
deplet
truli
appropri
control
lack
complement
c
deplet
mice
typic
left
protect
capac
whole
ab
intact
redund
mechan
adcc
well
cmc
incomplet
c
deplet
remain
possibl
moreov
crossspeci
transfer
ab
made
eg
human
ab
mice
nonhuman
primat
nhp
mous
ab
guinea
pig
nhp
posit
protect
result
eg
abmedi
protect
use
neg
result
fraught
antiab
aris
day
elimin
xenoab
also
fcfcr
interact
across
speci
problemat
best
search
anim
model
viral
diseas
classic
adapt
viru
serial
passag
sometim
fail
repeatedli
accumul
evid
natur
speci
barrier
given
viru
may
sometim
suggest
adapt
mutat
select
pressur
highli
improb
best
len
product
licensur
gold
write
establish
anim
model
predict
vaccin
effect
human
fraught
difficulti
low
success
rate
date
today
howev
mani
way
refashion
gene
human
viru
becom
like
caus
infect
diseas
nonhuman
speci
refashion
gene
unrel
viral
pathogen
eg
ordinarili
restrict
mous
nhp
express
incorpor
presumpt
protect
ag
human
pathogen
order
test
mechan
immun
target
antigen
render
nonhuman
speci
especi
mice
humanlik
suscept
engraft
human
cell
specif
gene
knockin
eg
human
receptor
viru
knockout
eg
hostrang
resist
factor
interferon
exampl
refer
given
tabl
note
previous
role
fcdepend
ab
activ
viral
clearanc
vivo
often
subordin
unfruit
eitheror
argument
rel
import
neutral
vs
nonneutr
ab
fact
mani
neutral
monoclon
mab
nmab
also
potent
celltarget
mab
ctmab
see
box
separ
effect
convent
nab
ab
also
exclus
exert
protect
effect
viral
agexpress
cell
literatur
tumor
immunolog
provid
use
guid
work
alreadi
welldescrib
continu
evolv
obvious
enough
mani
experi
could
replicatedand
ration
improv
antivir
ab
efficaci
vaccin
possibl
suggestedbi
test
capac
differ
ab
anim
model
differ
fcr
elimin
cell
constitut
express
viral
membran
ag
interest
illustr
figur
inde
work
alreadi
begun
addit
deeper
understand
new
direct
practic
reward
could
aris
establish
model
system
design
find
mechanist
correl
vitro
assay
vivo
elimin
viral
agexpress
cell
genuin
predict
model
could
facilit
bridg
studi
anim
model
human
efficaci
otherwis
barrier
licensur
vaccin
requir
invoc
anim
rule
illustr
figur
anim
model
may
employ
examin
effect
ab
given
variou
time
prophylact
therapeut
cognat
ag
case
viral
antigen
either
virion
cell
interpret
outcom
respect
straightforward
howev
behind
superfici
simplic
ab
includ
ctab
may
evok
fcdepend
antivir
effector
function
exist
complex
array
bind
signal
event
quantit
qualit
dimens
simplifi
illustr
figur
build
block
requir
reach
examin
abmedi
protect
knockout
mice
lack
discret
fcrbear
cell
lineag
presag
mice
newli
design
knockin
human
fcr
examin
tumor
immun
threshold
activ
variabl
wide
familiar
other
describ
next
proceed
bottommost
variabl
illustr
figur
import
ab
affin
cognat
viral
epitop
wellknown
foundat
immunolog
gener
rule
higher
affin
ab
activ
vitro
assay
protect
howev
affin
less
intrins
properti
abepitop
interact
measur
depend
sever
order
magnitud
upon
epitop
framework
conform
epitop
mask
dynam
chang
rearrang
occur
exampl
viral
spike
encount
receptor
proteas
ph
chang
ab
concentr
familiar
variabl
insofar
concentr
threshold
typic
observ
given
ab
monoclon
polyclon
appar
ineffectu
relat
howev
role
ab
biodistribut
concentr
necessari
site
activ
may
undermin
ab
effect
provid
insuffici
concentr
critic
site
includ
solid
tumor
brain
retina
intestin
lung
test
experiment
anim
model
describ
particular
hazard
opposit
end
ab
concentr
ie
impuls
empir
screen
ab
effect
use
highdos
treatment
contraind
singular
approach
phenomenon
highdos
prozon
presum
result
diminut
format
complex
necessari
robust
fcfcr
interact
akin
highdos
prozon
classic
immunoprecipit
reaction
anoth
explan
offer
outsid
bindingval
model
encount
high
ab
dose
high
ag
burden
result
exhaust
complement
compon
especi
consequ
diminish
overal
antibodi
effect
vivo
experiment
anim
model
rang
ab
dose
prefer
epitop
access
refer
longstand
observ
recapitul
differ
way
mani
viral
ag
viral
epitop
avail
ab
thu
fcdepend
immun
effector
mechan
select
time
transient
viral
entri
growth
cycl
use
word
cryptic
describ
epitop
appear
inaccess
intact
virion
yet
avail
virusinfect
cell
avail
may
instanc
inadequ
oversimplif
dynam
natur
viral
spike
protein
epitop
topolog
membran
proxim
determin
spatial
relationship
steric
hindranc
favor
one
type
fcmediat
effector
function
anoth
illustr
exampl
develop
therapeut
ab
strongli
impli
panel
influenzaspecif
mab
current
data
suggest
complementdepend
cytotox
abdepend
cellular
cytotox
favor
membraneproxim
epitop
wherea
ab
depend
cellular
phagocytosi
favor
epitop
posit
away
broadli
favor
optim
configur
given
effector
function
may
vari
differ
agab
pair
exemplifi
counterexampl
hivspecif
mab
membran
proxim
region
envelop
may
neglig
effector
function
gener
difficult
confound
mechanist
differ
vitro
assay
vivo
efficaci
decis
ag
concentr
densiti
target
cell
factor
shift
appar
effect
ab
ie
invers
relationship
ag
express
target
cell
amount
ab
requir
meet
threshold
fcdepend
activ
part
therapeut
efficaci
attribut
classic
model
experiment
anim
often
mice
challeng
day
infecti
viru
preced
sometim
follow
intervent
activ
passiv
immun
b
disambigu
collect
phenomena
affect
virion
spread
examin
close
requir
effect
fcmediat
effect
viral
agexpress
cell
one
challeng
mice
instead
cell
engin
express
viral
ag
somewhat
mimick
prior
model
tumor
immunotherapi
see
text
refer
mani
potenti
complex
opportun
step
includ
modifi
ab
highli
modifi
mice
high
express
tumor
cell
recent
shown
increas
express
target
ag
cell
one
way
improv
fcmediat
cell
clearanc
mice
otherwis
compromis
persist
viral
infect
fcfcr
affin
begin
quot
recent
paper
ravetch
group
leader
field
fcfcr
interact
murin
model
explor
biolog
signific
antibodi
fc
domain
rel
affin
activ
inhibitori
call
ai
ratio
determin
function
output
directli
correl
therapeut
efficaci
vivo
spawn
recent
effort
engin
ab
enhanc
activ
affin
embed
much
work
directli
observ
impli
import
isotyp
also
speci
match
establish
fcfcr
affin
human
mous
nonhuman
primat
nhp
fcr
nonequival
bind
given
ab
typic
human
chosen
type
nomenclatur
fcr
variou
speci
poor
guid
ab
affin
function
current
scientif
literatur
rich
recognit
natur
occur
fc
fcr
allel
variant
follow
structur
redesign
ab
molecul
optim
ab
glycosyl
ab
halflif
detail
outsid
scope
manuscript
variabl
cite
call
attent
caution
fcdepend
possibl
limit
singl
mab
may
view
cours
experi
alloster
chang
fc
phenomenon
remain
incomplet
resolv
term
biolog
signific
howev
improv
tool
structur
analysi
restor
possibl
allosteri
among
factor
may
contribut
addit
synergist
ab
function
thu
subset
mab
presum
subset
natur
polyclon
ab
bind
fab
cognat
epitop
result
alloster
figur
concept
repres
build
block
effect
celltarget
ab
immun
viral
infect
see
text
detail
mani
factorseach
quantit
qualit
dimensioncontribut
addit
synergist
reach
threshold
antivir
activ
meet
standard
protect
efficaci
defin
box
threshold
constant
vari
individu
host
speci
viru
biotyp
dose
rout
infect
etc
short
figur
intend
illustr
fcmediat
aspect
abmedi
immun
interrel
part
complex
adapt
system
aros
coevolut
host
viru
adequ
exploit
concept
vaccin
therapeut
ab
requir
either
empir
good
fortun
key
almost
licens
vaccin
understand
allow
ration
improv
design
search
statist
mechanist
correl
protect
assay
combin
sever
factor
may
favor
chang
fc
turn
promot
higher
affin
fc
fcr
observ
absenc
ag
implic
depend
upon
assay
vitro
result
may
inadequ
predictor
fcmediat
function
activ
ab
differ
kind
allosteri
seen
two
mab
synerg
basi
fab
bind
one
part
ag
molecul
promot
bind
second
mab
recogn
differ
epitop
ag
newer
anim
model
may
add
clariti
function
import
alloster
interact
abmedi
protect
virus
import
effect
fcrbear
cell
type
underestim
especi
crossspeci
transfer
human
ig
transfer
nhp
mice
complex
sever
due
interspeci
differ
fcr
affin
given
mab
interspeci
differ
cell
type
variou
fcr
found
virolog
circl
complement
activ
complement
deposit
receiv
diminish
attent
presum
ablat
complement
murin
model
tend
leav
intact
protect
antivir
capac
ab
howev
dismiss
complement
like
imprud
antibodi
therapi
human
tumor
show
import
addit
augment
effect
mediat
complement
signal
figur
attent
must
paid
addit
synergist
fcmediat
effect
ab
cumul
determin
whether
threshold
reach
ab
effect
vivo
potenti
restor
inhibit
ctab
activ
emerg
opportun
understand
improv
protect
capac
ctab
virus
tumor
immunolog
led
way
ab
alreadi
clinic
trial
show
clinic
promis
way
dampen
nt
eat
signal
otherwis
spare
tumor
cell
destruct
monocyt
macrophag
mani
poxvirus
explicitli
express
homolog
complex
virus
herpesvirus
express
homolog
immunomodulatori
protein
potenti
shift
threshold
antivir
attent
escap
notic
may
first
mani
opportun
counteract
known
perhap
unknown
viral
protein
undermin
host
immun
respons
includ
fcdepend
activ
ventur
testabl
hypothesi
could
part
mechan
herpesviru
subunit
hzsu
consist
one
famili
herpesviru
protein
ge
bind
fc
serv
effect
vaccin
evok
ab
restor
otherwiseinhibit
fcrdepend
ctab
activ
element
abmedi
antivir
immun
appear
larg
complet
independ
fc
function
other
highli
reliant
fc
order
exert
biolog
effect
regist
protect
activ
box
ab
ctab
share
number
therapeut
anticanc
ab
aim
arrest
destroy
cell
recogn
ab
mechanist
relev
glean
extens
research
clinic
trial
antitumor
ctab
howev
efficaci
antivir
ctab
differ
complex
due
typic
incapac
obtain
human
protect
data
longstand
problem
inher
classic
anim
model
viral
diseas
recent
newer
approach
tabl
allow
increas
compat
given
viru
cellexpress
antigen
suscept
anim
model
fcfcr
interact
popul
fcrbear
effector
cell
etc
brief
review
intend
highlight
cite
recent
literatur
first
point
toward
almost
bewild
complex
factor
intrud
upon
subset
protect
antivir
mechan
fcdepend
feasibl
approach
achiev
clariti
like
given
viru
uniqu
structur
biolog
uniqu
pathogenet
profil
chosen
anim
model
fcdepend
abdirect
mechan
prove
reliabl
import
other
moreov
concept
illustr
figur
meant
understood
scalabl
import
rare
ever
suffici
achiev
threshold
achiev
enough
efficaci
adequ
suppress
viral
replic
prevent
viral
diseas
encourag
experiment
tool
includ
shown
tabl
emerg
affirm
refut
truth
biolog
import
concept
previous
mire
complex
increas
degre
ration
select
design
optim
effect
mab
mean
elicit
vaccin
inform
antivir
research
similarli
refin
select
continu
improv
vitro
assay
statist
correl
mechanist
correl
protect
still
final
proof
continu
empir
matter
find
safe
effect
co
gl
share
discuss
lab
meet
period
mani
month
develop
perspect
emphas
cite
refer
manuscript
craft
primari
draft
improv
approv
co
gl
fund
author
provid
follow
grant
contract
niaidnih
dod
grant
bill
melinda
gate
foundat
